Read before buying drugs   
RXMedsDoctor.net

Select Drugs:
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Z

Zoladex

No Prescription

Zoladex relieves the symptoms of advanced prostate cancer in men and advanced breast cancer in premenopausal women. In combination with other forms of therapy, it is also prescribed during treatment of early prostate cancer.

In addition, it can be prescribed in the treatment of endometriosis, a condition in which tissue from the lining of the uterus invades the abdomen. If you are scheduled for surgical removal of the lining, the drug may be prescribed to thin the lining prior to the operation.

Zoladex works by reducing levels of testosterone in men and estrogen in women. These hormones can encourage the growth of certain cancers.

Side Effects

Zoladex side effects that you should report to your health care professional or doctor as soon as possible:
- Weight Gain;
- Weakness;
- Weak Heart;
- Voice Changes;
- Vaginal Inflammation;
- Vaginal Dryness;
- Urinary Problems;
- Sweating;
- Sore Throat;
- Sexual Impairment;
- Rash;
- Pain;
- Nervousness;
- Nausea;
- Lung Problems;
- Loss Of Breast Tissue In Women;
- Loss Of Appetite;
- Lethargy;
- Insomnia;
- Infection;
- Hot Flashes;
- Headache;
- Hair Growth In Women;
- Fluid Retention And Swelling;
- Flu Symptoms;
- Emotional Problems;
- Dizziness;
- Depression;
- Change In Sex-Drive;
- Breast Tenderness Or Pain;
- Breast Development In Men Or Enlargement In Women;
- Application Site Reactions;
- Acne;

Dosage

Typically, the doctor will implant a dose of 3.6 mg every 4 weeks. Treatment for endometriosis lasts no longer than 6 months. Cancer therapy generally continues for a longer term.

For prostate cancer, the doctor can administer a longer lasting implant of 10.8 mg every 12 weeks. When the drug is given with Flutamide, the treatment is one 3.6-millgram implant followed by one 10.8-mg implant 4 weeks later.

If the drug is being prescribed in preparation for endometrial surgery, you'll receive 1 or 2 implants before the operation.

(c) 2017